Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669614 | 1.00 | GPR119 (0.36) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL786607 | 0.83 | HTT (0.41) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL26167034 | 0.82 | HTT (0.38) | HTTVSIRCD274 | |
| SCHEMBL15932016 | 0.81 | GPR119 (0.33) | GPR119MAOAMAOBVSIRCD274 | |
| SCHEMBL24086174 | 0.79 | VSIR (0.35) | VSIRCD274 | |
| SCHEMBL22139805 | 0.79 | VSIR (0.46) | VSIRCD274 | |
| SCHEMBL13319540 | 0.78 | — | — | |
| SCHEMBL13489687 | 0.78 | GPR119 (0.32) | GPR119MAOAMAOB | |
| SCHEMBL21398054 | 0.77 | GPR119 (0.36) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL1091056 | 0.77 | GPR119 (0.43) | GPR119MAOAMAOBHTTIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044303-A1 | 1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
| US-8153626-B2 | Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | BRS3, BRSK1, BRSK2 | GPR119 4/4885MAOA 4363/4885MAOB 3789/4885 |
| US-20180044303-A1 | 1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | PDCD1, PDCD1LG2, CD274 | GPR119 3261/4885MAOA 3136/4885MAOB 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.